Evolocumab

What it is

Evolocumab is a fully human monoclonal antibody of the IgG2 class, given by subcutaneous injection rather than by mouth, that binds and blocks a liver protein called PCSK9. It is supplied as a 140 mg autoinjector or prefilled syringe given every two weeks, or as a 420 mg monthly dose. It is used alongside statins and diet, not instead of them.

What the research says

It lowers LDL cholesterol by around 59 to 63% on top of a statin. In FOURIER, the 27,564-patient outcome trial, that translated into fewer cardiovascular events: 9.8% of people on evolocumab reached the primary composite endpoint versus 11.3% on placebo over a median 2.2 years, an absolute difference of about 1.5 percentage points. Cardiovascular death and death from any cause did not differ. A Cochrane review graded the event reduction as high-certainty evidence while rating the mortality result, also high certainty, as showing no difference. A prespecified cognition substudy found no difference in cognitive function.

Evidence grade: Well established.

How it works

Drug class: PCSK9 inhibitor (human monoclonal antibody)

The liver clears LDL cholesterol from the blood using LDL receptors on its cells. A protein called PCSK9 latches onto those receptors and sends them to be destroyed, so fewer are available. Evolocumab is an antibody that binds PCSK9 and stops it doing that, leaving more receptors to pull LDL out of the blood. (Source 1)

What it is used for

• FOURIER randomised 27,564 people with atherosclerotic cardiovascular disease already on statins. The primary composite endpoint fell from 11.3% to 9.8% over a median 2.2 years, a hazard ratio of 0.85. Cardiovascular death was 1.7% on placebo and 1.8% on evolocumab, hazard ratio 1.05, and death from any cause did not differ either. Evidence: established. (Source 2)
• LDL cholesterol fell by about 59% at 48 weeks in FOURIER and by 44.5% versus 6.2% on placebo in the paediatric HeFH trial. These are lipid outcomes, not event outcomes, in the familial hypercholesterolaemia populations. Evidence: established. (Source 2)
• TESLA Part B randomised only 50 patients for 12 weeks and found LDL cholesterol fell 30.9% more than on placebo. No cardiovascular outcome trial exists in this rare condition, so the approval rests on a lipid endpoint in a very small trial. Evidence: limited. (Source 3)
• EBBINGHAUS, a prespecified substudy in 1,204 FOURIER patients, found no significant difference in executive function, working memory, episodic memory or psychomotor speed over a median 19 months, and no association between LDL level and cognitive change. Evidence: not-supported. (Source 4)

Interactions

• Statins (used together by design) (clinical trial): Evolocumab was studied on top of statin therapy rather than instead of it; in FOURIER every participant was on a statin, and the label positions it as an adjunct to diet and exercise. (Source 5)

Stopping it

• There is no withdrawal syndrome described, but the effect is not durable: PCSK9 is released from blockade and LDL cholesterol rises again as the antibody clears, so stopping returns the person to their untreated lipid level. (Source 6)
• Delaying treatment appears to cost events rather than merely postponing benefit: in the open-label extension, people who had received placebo during the parent trial continued to have more cardiovascular events than those who started evolocumab earlier. (Source 7)

What goes wrong

Injection site reactions were the one adverse event clearly more common with evolocumab than placebo in FOURIER. (Source 2)

• Randomized trial, High certainty.
• Size: 27,564 patients.
• Who: Adults with established cardiovascular disease on statin therapy.
• How long: Median 2.2 years.
• Result: Injection-site reactions 2.1% vs 1.6%. No significant difference between groups for other adverse events, including new-onset diabetes and neurocognitive events.
• Funding: Industry-funded (Amgen)

There was no significant difference between the study groups with regard to adverse events (including new-onset diabetes and neurocognitive events), with the exception of injection-site reactions, which were more common with evolocumab (2.1% vs. 1.6%).

In the pooled controlled trials, injection site reactions occurred in 3.2% on evolocumab versus 3.0% on placebo, and hypersensitivity reactions in 5.1% versus 4.7%. (Source 8)

• Randomized trial, Moderate certainty.
• Size: Pooled from one 52-week trial and seven 12-week trials; 2,651 patients received evolocumab in 8 placebo-controlled trials.
• Who: Adults with primary hypercholesterolaemia.
• How long: Mean exposure 20 weeks, median 12 weeks in the pool.
• Result: Injection site reactions 3.2% vs 3.0%; discontinuation for them 0.1% vs 0%. Hypersensitivity reactions 5.1% vs 4.7%, most commonly rash (1.0% vs 0.5%), eczema (0.4% vs 0.2%), erythema (0.4% vs 0.2%) and urticaria (0.4% vs 0.1%).
• Funding: Manufacturer trial data reproduced in the FDA label (Amgen), effective 2026-08-19.

Local Injection Site Reactions Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising. The proportions of patients who discontinued treatment due to local injection site reactions in REPATHA-treated patients and placebo-treated patients were 0.1% and 0%, respectively. Hypersensitivity Reactions Hypersensitivity reactions occurred in 5.1% and 4.7% of REPATHA-treated and placebo-treated patients, respectively. The most common hypersensitivity reactions were rash (1.0% versus 0.5% for REPATHA and placebo, respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus 0.2%), and urticaria (0.4% versus 0.1%).

New-onset diabetes was slightly more common on evolocumab than placebo in the cardiovascular outcomes trial, a difference the trial did not find significant. (Source 9)

• Randomized trial, Moderate certainty.
• Size: 27,525 patients received at least one dose; 16,676 had no diabetes at baseline.
• Who: Adults with established cardiovascular disease, mean age 62.5 years, 25% women.
• How long: Median exposure 24.8 months.
• Result: Diabetes mellitus reported in 8.8% on evolocumab vs 8.2% on placebo. Among those without diabetes at baseline, new-onset diabetes 8.1% vs 7.7%.
• Funding: Manufacturer trial data reproduced in the FDA label (Amgen), effective 2026-08-19.

Common adverse reactions (> 5% of patients treated with REPATHA and occurring more frequently than placebo) included diabetes mellitus (8.8% REPATHA, 8.2% placebo), nasopharyngitis (7.8% REPATHA, 7.4% placebo), and upper respiratory tract infection (5.1% REPATHA, 4.8% placebo). Among the 16,676 patients without diabetes mellitus at baseline, the incidence of new-onset diabetes mellitus during the trial was 8.1% in patients treated with REPATHA compared with 7.7% in patients that received placebo.

Serious hypersensitivity reactions including angioedema have been reported and make evolocumab contraindicated in anyone who has had one. (Source 10)

• Case series, Very low certainty.
• Size: Not quantifiable; voluntary postmarketing reports from a population of uncertain size.
• Who: Patients treated with evolocumab after approval.
• How long: Post-approval surveillance.
• Result: No rate is given. The label instructs clinicians to discontinue the drug for serious hypersensitivity reactions and contraindicates it after one.
• Funding: Regulatory label text (Amgen / US FDA), effective 2026-08-19.

Hypersensitivity reactions, including angioedema, have been reported in patients treated with REPATHA. If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with REPATHA, treat according to the standard of care, and monitor until signs and symptoms resolve. REPATHA is contraindicated in patients with a history of serious hypersensitivity reactions to evolocumab or any excipient in REPATHA

In a 52-week placebo-controlled trial the commonest adverse reactions on evolocumab were nasopharyngitis and upper respiratory infection, with discontinuation for adverse reactions in 2.2% versus 1% on placebo. (Source 11)

• Randomized trial, Moderate certainty.
• Size: 901 patients (599 evolocumab, 302 placebo)
• Who: Adults with primary hypercholesterolaemia, mean age 56, 52% women.
• How long: 52 weeks of 420 mg monthly.
• Result: Nasopharyngitis 10.5% vs 9.6%; upper respiratory tract infection 9.3% vs 6.3%; influenza 7.5% vs 6.3%; back pain 6.2% vs 5.6%; injection site reactions 5.7% vs 5.0%; myalgia 4.0% vs 3.0%. Discontinuation for adverse reactions 2.2% vs 1%.
• Funding: Manufacturer trial data reproduced in the FDA label (Amgen), effective 2026-08-19.

Adverse reactions led to discontinuation of treatment in 2.2% of REPATHA-treated patients and 1% of placebo-treated patients. The most common adverse reaction that led to REPATHA treatment discontinuation and occurred at a rate greater than placebo was myalgia (0.3% versus 0% for REPATHA and placebo, respectively). Table 1. Adverse Reactions Occurring in ≥ 3% of REPATHA-treated Patients and More Frequently than with Placebo in a 52-Week Trial Placebo (N = 302) % REPATHA (N = 599) % Nasopharyngitis 9.6 10.5 Upper respiratory tract infection 6.3 9.3 Influenza 6.3 7.5 Back pain 5.6 6.2 Injection site reactions 5.0 5.7 Cough 3.6 4.5 Urinary tract infection 3.6 4.5 Sinusitis 3.0 4.2 Headache 3.6 4.0 Myalgia 3.0 4.0

Injection site reactions were slightly more common with evolocumab than placebo in the pooled controlled trials, and were most often erythema, pain and bruising. (Source 12)

• Randomized trial, Certainty not rated.
• Size: Pooled controlled trials reported in label section 6.1.
• Who: Adults in the pooled placebo-controlled trials.
• How long: 12 to 20 weeks.
• Result: 3.2 percent on evolocumab against 3.0 percent on placebo; discontinuation for this reason 0.1 percent against 0 percent.
• Funding: industry-funded.

Injection site reactions occurred in 3.2% and 3.0% of REPATHA-treated and placebo-treated patients, respectively. The most common injection site reactions were erythema, pain, and bruising.

What the evidence supports

In FOURIER, evolocumab reduced the primary composite cardiovascular endpoint from 11.3% to 9.8% over a median 2.2 years. (Source 2)

• Randomized trial, High certainty.
• Size: 27,564 patients.
• Who: Adults with atherosclerotic cardiovascular disease and LDL cholesterol of 70 mg/dL or higher on statin therapy; 81% had a prior myocardial infarction.
• How long: Median follow-up 2.2 years.
• Result: Primary endpoint 1344 (9.8%) vs 1563 (11.3%); hazard ratio 0.85 (95% CI 0.79 to 0.92; P<0.001). Absolute risk difference about 1.5 percentage points, roughly 67 people treated for 2.2 years per event avoided. Key secondary endpoint 5.9% vs 7.4%; hazard ratio 0.80 (0.73 to 0.88). LDL cholesterol fell 59% from a median 92 to 30 mg/dL.
• Funding: Industry-funded (Amgen); several authors are Amgen employees.

Relative to placebo, evolocumab treatment significantly reduced the risk of the primary end point (1344 patients [9.8%] vs. 1563 patients [11.3%]; hazard ratio, 0.85; 95% confidence interval [CI], 0.79 to 0.92; P<0.001) and the key secondary end point (816 [5.9%] vs. 1013 [7.4%]; hazard ratio, 0.80; 95% CI, 0.73 to 0.88; P<0.001).

In the open-label extension, up to 8.4 years of evolocumab exposure produced no excess of serious adverse events, and the group randomised to evolocumab in the parent trial went on to have fewer events including cardiovascular death. (Source 13)

• Randomized trial, Low certainty.
• Size: 6,635 patients (3,355 originally randomised to evolocumab, 3,280 to placebo)
• Who: FOURIER completers at participating sites in the United States and Europe.
• How long: Median 5.0 years of open-label follow-up; maximum parent-plus-extension exposure 8.4 years.
• Result: Primary composite hazard ratio 0.85 (95% CI 0.75-0.96; P=0.008); CV death, MI or stroke 0.80 (0.68-0.93; P=0.003); cardiovascular death 0.77 (0.60-0.99; P=0.04). Serious adverse events, muscle events, new-onset diabetes, haemorrhagic stroke and neurocognitive events did not exceed the placebo rates from the parent study. Note this is an open-label, non-randomised comparison of legacy treatment allocation.
• Funding: Industry-funded (Amgen)

Incidences of serious adverse events, muscle-related events, new-onset diabetes, hemorrhagic stroke, and neurocognitive events with evolocumab long term did not exceed those for placebo-treated patients during the parent study and did not increase over time. During the FOURIER-OLE follow-up period, patients originally randomized in the parent trial to evolocumab versus placebo had a 15% lower risk of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina or coronary revascularization (hazard ratio, 0.85 [95% CI, 0.75-0.96]; P=0.008); a 20% lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80 [95% CI, 0.68-0.93]; P=0.003); and a 23% lower risk of cardiovascular death (hazard ratio, 0.77 [95% CI, 0.60-0.99]; P=0.04).

In homozygous familial hypercholesterolaemia, evolocumab lowered LDL cholesterol by 30.9% more than placebo in a 50-patient 12-week trial. (Source 3)

• Randomized trial, Low certainty.
• Size: 50 randomised, 49 received drug and completed (33 evolocumab, 16 placebo)
• Who: Patients aged 12 and over with homozygous familial hypercholesterolaemia on stable lipid-lowering therapy, not on apheresis.
• How long: 12 weeks.
• Result: Ultracentrifugation LDL cholesterol fell 30.9% versus placebo (95% CI -43.9% to -18.0%; p<0.0001). Treatment-emergent adverse events in 12 (36%) of 33 on evolocumab versus 10 (63%) of 16 on placebo. No cardiovascular outcomes were measured.
• Funding: Industry-funded (Amgen Inc)

Compared with placebo, evolocumab significantly reduced ultracentrifugation LDL cholesterol at 12 weeks by 30·9% (95% CI -43·9% to -18·0%; p<0·0001).

In children aged 10 to 17 with heterozygous familial hypercholesterolaemia, evolocumab lowered LDL cholesterol by 38.3 percentage points more than placebo. (Source 14)

• Randomized trial, Moderate certainty.
• Size: 157 patients (104 evolocumab, 53 placebo)
• Who: Patients 10 to 17 years old with heterozygous familial hypercholesterolaemia on stable lipid-lowering treatment.
• How long: 24 weeks.
• Result: Mean percent change in LDL cholesterol -44.5% vs -6.2%, difference -38.3 percentage points (P<0.001); absolute change -77.5 vs -9.0 mg/dL, difference -68.6 mg/dL. Adverse event incidence similar between groups. Lipid endpoints only; no cardiovascular outcomes.
• Funding: Industry-funded (Amgen); Amgen employees among the authors.

At week 24, the mean percent change from baseline in LDL cholesterol level was -44.5% in the evolocumab group and -6.2% in the placebo group, for a difference of -38.3 percentage points (P<0.001).

What the evidence does not support

Cardiovascular death in FOURIER was no lower on evolocumab, and neither was death from any cause. (Source 15)

• Randomized trial, High certainty.
• Size: 27,564 patients (13,784 evolocumab, 13,780 placebo)
• Who: Adults with established cardiovascular disease on statin therapy.
• How long: Median follow-up 26 months.
• Result: Time to CV death 240 (1.7%) on placebo vs 251 (1.8%) on evolocumab, hazard ratio 1.05 (95% CI 0.88, 1.25). Death by any cause 426 (3.1%) vs 444 (3.2%), hazard ratio 1.04 (0.91, 1.19). Myocardial infarction and stroke did fall.
• Funding: Manufacturer trial data reproduced in the FDA label (Amgen), effective 2026-08-19.

Other secondary endpoints Time to CV death 240 (1.7) 0.8 251 (1.8) 0.8 1.05 (0.88, 1.25) Time to death by any cause 426 (3.1) 1.4 444 (3.2) 1.5 1.04 (0.91, 1.19)

A prespecified cognition substudy found no difference in cognitive function between evolocumab and placebo. (Source 4)

• Randomized trial, Moderate certainty.
• Size: 1,204 patients.
• Who: A subgroup of FOURIER participants, all on statin therapy.
• How long: Median 19 months.
• Result: Spatial working memory strategy index change -0.21 +/- 2.62 on evolocumab vs -0.29 +/- 2.81 on placebo (P<0.001 for noninferiority; P=0.85 for superiority). No significant differences in working memory, episodic memory or psychomotor speed, and no association between LDL level and cognitive change.
• Funding: Industry-funded (Amgen); Amgen employees are among the authors.

There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively). In an exploratory analysis, there were no associations between LDL cholesterol levels and cognitive changes.

Cochrane notes that the evidence for PCSK9 antibodies against active comparators is much weaker and that low- to medium-risk populations are barely studied. (Source 16)

• Systematic review, Low certainty.
• Size: 24 studies, 60,997 participants.
• Who: Mostly people with established cardiovascular disease or already at high risk.
• How long: At least 24 weeks per trial.
• Result: The review rates head-to-head comparisons against active treatment as very low to low certainty and says evidence in low- to medium-risk settings is minimal.
• Funding: Cochrane review (independent)

The evidence base of PCSK9 inhibitors compared with active treatment is much weaker (low very- to low-certainty evidence) and it is unclear whether evolocumab or alirocumab might be effectively used as replacement therapies. Related, most of the available studies preferentially enrolled people with either established CVD or at a high risk already, and evidence in low- to medium-risk settings is minimal.

In FOURIER, hospitalization for unstable angina, one of the five components of the primary endpoint, showed no difference between evolocumab and placebo. (Source 17)

• Randomized trial, Certainty not rated.
• Size: 27,564 patients.
• Who: Adults with established atherosclerotic cardiovascular disease on statin therapy.
• How long: Median 2.2 years.
• Result: 239 (1.7 percent) on evolocumab against 236 (1.7 percent) on placebo, hazard ratio 0.99 (95% CI 0.82, 1.18)
• Funding: industry-funded.

Limit of this finding: The label marks this row as an ad hoc analysis that was not prespecified, so it is reported for completeness of the primary endpoint's components rather than as a planned test.

Time to first hospitalization for unstable anginaNot a prespecified endpoint; an ad hoc analysis was performed to ensure results are provided for each individual component of the primary endpoint. 239 (1.7) 0.8 236 (1.7) 0.8 0.99 (0.82, 1.18)

Where the evidence is mixed

A Cochrane review graded evolocumab's cardiovascular benefit as high certainty with an absolute risk difference of about 2%, while finding no mortality benefit, also at high certainty. (Source 18)

• Systematic review, High certainty.
• Size: 24 studies, 60,997 participants overall; evolocumab versus placebo analyses used 29,432 participants across 3 studies.
• Who: People on background lipid-lowering treatment or lifestyle counselling, mostly with established cardiovascular disease or high risk.
• How long: Trials with at least 24 weeks of follow-up.
• Result: Evolocumab vs placebo: CVD risk difference -2% (OR 0.84, 95% CI 0.78 to 0.91); mortality risk difference less than 1% (OR 1.04, 95% CI 0.91 to 1.19); myocardial infarction risk difference -1% (OR 0.72, 0.64 to 0.82); any stroke OR 0.79 (0.65 to 0.94). All high-certainty.
• Funding: Cochrane review (independent)

Limit of this finding: The review's own wording is loose in two places and is quoted unchanged. It reports the mortality odds ratio as 1.04 (95% CI 0.91 to 1.19), an interval that spans 1 and so shows no difference either way, while describing the risk difference as "less than 1%"; and it describes the stroke risk difference as "less than -1%", which reads as a bound rather than an estimate. A reader should take from this that evolocumab did not reduce death in these trials, and that the absolute benefits on cardiovascular events and stroke are small even though the review grades the certainty as high.

Compared to placebo the evolocumab, for CVD, the RD was -2% (OR 0.84, 95% CI 0.78 to 0.91; 3 studies, 29,432 participants; high-certainty evidence);

Where the research disagrees

Whether evolocumab saves lives or only prevents non-fatal events

• Sabatine and colleagues, FOURIER investigators, randomised controlled trial of 27,564 patients: These findings show that patients with atherosclerotic cardiovascular disease benefit from lowering of LDL cholesterol levels below current targets. (Source 5)
• The FOURIER mortality data as recorded in the FDA label, the same trial's secondary endpoints: Time to CV death 240 (1.7) 0.8 251 (1.8) 0.8 1.05 (0.88, 1.25) (Source 15)
• Schmidt and colleagues, 2020 Cochrane review, systematic review and meta-analysis: for mortality, RD was less than 1% (OR 1.04, 95% CI 0.91 to 1.19; 3 studies, 29,432 participants; high-certainty evidence); (Source 18)

How much

• Reference intake: Dosing is set by the prescriber, not by the reader. As a regulatory position, the 2026 US label records 140 mg every 2 weeks or 420 mg once monthly by subcutaneous injection for adults at increased cardiovascular risk or with hypercholesterolaemia. (Source 19)
• Upper limit: The label sets no upper intake level in the nutrient sense. The highest regimen it describes is 420 mg every 2 weeks, reserved for homozygous familial hypercholesterolaemia that has not responded in 12 weeks or for people on lipid apheresis. (Source 19)
• Studied: FOURIER gave 140 mg every 2 weeks or 420 mg monthly to 13,784 people for a median of 2.2 years; 86% used the every-2-week regimen. (Source 2)
• Studied: TESLA Part B gave 420 mg every 4 weeks for 12 weeks to patients with homozygous familial hypercholesterolaemia. (Source 3)
• Studied: HAUSER-RCT gave 420 mg monthly for 24 weeks to 104 patients aged 10 to 17 with heterozygous familial hypercholesterolaemia. (Source 14)

A common belief, and what the research shows

The belief: Because evolocumab cuts LDL cholesterol by about 60%, it must cut heart deaths by a similar amount.

What the research shows: It does not. In FOURIER the composite endpoint fell from 11.3% to 9.8% over a median 2.2 years, and cardiovascular death did not fall at all: 240 (1.7%) on placebo against 251 (1.8%) on evolocumab, hazard ratio 1.05 (95% CI 0.88, 1.25). The label's own table records it: "Other secondary endpoints Time to CV death 240 (1.7) 0.8 251 (1.8) 0.8 1.05 (0.88, 1.25) Time to death by any cause 426 (3.1) 1.4 444 (3.2) 1.5 1.04 (0.91, 1.19)" The benefit that was seen was in myocardial infarction, stroke and revascularisation.

Questions and answers

What is it?

Evolocumab is a laboratory-made human antibody given by injection under the skin, usually 140 mg every two weeks or 420 mg once a month. It is used alongside diet, exercise and statins to lower LDL cholesterol and, in people at increased risk, to reduce major cardiovascular events. It is approved in adults and, for familial hypercholesterolaemia, in children aged 10 and over. (Source 20)

What does it do in the body?

The liver pulls LDL cholesterol out of the blood using LDL receptors. A protein called PCSK9 binds those receptors and marks them for destruction, so the liver has fewer of them. Evolocumab blocks PCSK9, which leaves more receptors in place and more LDL cleared from the blood. (Source 1)

Is it good or bad for you?

On the evidence it helps a specific group: people who already have atherosclerotic cardiovascular disease and are already on a statin. In that group FOURIER showed the composite endpoint fall from 11.3% to 9.8% over about two years. It did not reduce cardiovascular death or death from any cause. Cochrane rates the event reduction as high-certainty but says evidence in lower-risk people is minimal. Harms are modest, mainly injection site reactions. (Source 2)

How do you get more of it?

Evolocumab is a prescription biologic injected under the skin. It cannot be obtained from food or supplements and there is no oral form. The schedule in the trials and the label is 140 mg every two weeks or 420 mg monthly; dosing is a matter for the prescriber, not the reader. (Source 19)

If it is harmful, what reduces it?

Nothing is needed to remove it actively: it is an antibody that clears on its own, and once blood levels drop below detection the PCSK9 it was blocking returns toward baseline, so LDL cholesterol rises again. If a serious allergic reaction occurs the label says to stop the drug and treat to standard of care. (Source 6)

Why might someone be low in it or missing it?

Nobody is deficient in evolocumab, because it is a manufactured medicine rather than something the body makes. The reasons a person may not be on it are clinical and practical: it is contraindicated after a serious hypersensitivity reaction to it, it is positioned as an add-on for people already on diet, exercise and statins, and Cochrane notes that trials have mostly enrolled people with established disease or high risk. (Source 16)

Which whole foods contain it or feed it?

No food contains evolocumab or anything that acts on PCSK9 the way it does. The label frames the drug as an addition to diet and exercise rather than a replacement for them, and every participant in the outcome trial was also on a statin. (Source 20)

What happens if you do not have it?

Not taking it means LDL cholesterol stays at its statin-treated level and the cardiovascular risk stays where the placebo arm sat: 11.3% reached the composite endpoint over a median 2.2 years against 9.8% on the drug. In homozygous familial hypercholesterolaemia, where conventional treatments work poorly, the untreated LDL level is substantially higher than on evolocumab. (Source 15)

How can you test for it?

The relevant test is an LDL cholesterol blood measurement, which is a standard, well-validated lipid panel. The label says the LDL-lowering effect can be seen as early as 4 weeks and that on the monthly regimen LDL can vary across the dosing interval, so it recommends measuring just before the next dose. In the trials, LDL fell about 59% at 48 weeks. (Source 2)

References

1. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 12.1 Mechanism of Action (Full Prescribing Information). 2026. Read the source
2. New England Journal of Medicine. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. [RESULTS]. 2017. PMID 28304224, DOI 10.1056/NEJMoa1615664. Read the source
3. The Lancet. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. [FINDINGS]. 2015. PMID 25282520, DOI 10.1016/S0140-6736(14)61374-X. Read the source
4. New England Journal of Medicine. Cognitive Function in a Randomized Trial of Evolocumab (EBBINGHAUS).. 2017. PMID 28813214, DOI 10.1056/NEJMoa1701131. Read the source
5. New England Journal of Medicine. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. [CONCLUSIONS]. 2017. PMID 28304224, DOI 10.1056/NEJMoa1615664. Read the source
6. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 12.2 Pharmacodynamics (Full Prescribing Information). 2026. Read the source
7. Circulation. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. [CONCLUSIONS]. 2022. PMID 36031810, DOI 10.1161/CIRCULATIONAHA.122.061620. Read the source
8. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 6.1 Clinical Trials Experience, local injection site reactions and hypersensitivity reactions in pooled controlled trials. 2026. Read the source
9. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 6.1 Clinical Trials Experience, Adverse Reactions in the CV Outcomes Trial. 2026. Read the source
10. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 5.1 Hypersensitivity Reactions (Warnings and Precautions, Full Prescribing Information). 2026. Read the source
11. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 6.1 Clinical Trials Experience, Table 1 adverse reactions in a 52-week trial. 2026. Read the source
12. DailyMed (Amgen Inc.). REPATHA (evolocumab) label, section 6.1 Clinical Trials Experience, Local Injection Site Reactions. 2026. Read the source
13. Circulation. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease. [RESULTS]. 2022. PMID 36031810, DOI 10.1161/CIRCULATIONAHA.122.061620. Read the source
14. New England Journal of Medicine. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. [RESULTS]. 2020. PMID 32865373, DOI 10.1056/NEJMoa2019910. Read the source
15. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 14 CLINICAL STUDIES, Table 3. Effect of REPATHA on CV Events in Patients with Established CVD in FOURIER. 2026. Read the source
16. Cochrane Database of Systematic Reviews. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Authors’ conclusions.. 2020. PMID 33078867, DOI 10.1002/14651858.CD011748.pub3. Read the source
17. DailyMed (Amgen Inc.). REPATHA (evolocumab) label, section 14 Clinical Studies, FOURIER Table 3, final row: time to first hospitalization for unstable angina. 2026. Read the source
18. Cochrane Database of Systematic Reviews. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.. 2020. PMID 33078867, DOI 10.1002/14651858.CD011748.pub3. Read the source
19. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 2.1 Recommended Dosage (Full Prescribing Information). 2026. Read the source
20. Amgen USA Inc. / DailyMed (U.S. FDA Structured Product Label, effective 2026-08-19). REPATHA (evolocumab) injection - 1 INDICATIONS AND USAGE (Full Prescribing Information). 2026. Read the source